Patanol

Patanol®

Olopatadine Ophthalmology An agent used to relieve eye itching in allergic conjunctivitis
References in periodicals archive ?
Our study forecasts sales of 27 marketed drugs, including these brands: - Lucentis - Eylea - Restasis - Vigamox - Pataday/ Patanol - Jetrea - Lumigan and Ganfort - Xalatan/Xalacom - Zioptan - Cravit Discover how high revenues can go.
Our study forecasts sales of 27 marketed drugs, including these brands: -- Lucentis -- Eylea -- Restasis -- Vigamox -- Pataday/ Patanol -- Jetrea -- Lumigan and Ganfort -- Xalatan/Xalacom -- Zioptan -- Cravit
7 percent "due to strong contributions" from AcrySof intraocular lenses, "healthy growth" in sales of glaucoma products and the impact of a severe allergy season on sales of Patanol and Pataday ophthalmic solutions and Patanase nasal spray.
Eye drops can ease itchy, red, or watery eyes by washing allergens from the eye (as with Bausch & Lomb's Advanced Eye Relief Eye Wash) or by acting as an antihistamine (as in the case of Visine-A, Patanol and Optivar).
Insurance companies may opt to stop paying for prescription eye drops such as Patanol, Optivar, and Elestat since they are very similar to the new OTC options.
Alcon pharmaceuticas Patanol continues to lead the market with a 48% share, followed by its Pataday, with a market share of 27% in 2009.
Our work shows you revenue forecasts for 20 top products, including Lucentis, Eylea, Visudyne, Xalatan/Xalacom, Patanol and Restasis.
As regards products, despite a decline in sales of Durotep, an analgesic for persistent cancer pain due to the ending of a joint sales contract, strong sales were maintained by Allelock, an antiallergic agent, Depakene, an anti-epileptic agent, and Patanol, an antiallergic ophthalmic solution, while sales of Coversyl, an ACE inhibitor for treatment of hypertension, that commenced in April, 2008, also performed well and contributed to growth in sales.
Alcon Receives Marketing Approval for Patanol in Japan 91
As regards sales by product, sales of Durotep, an analgesic for persistent cancer pain declined, due to the ending of a joint sales contract, but strong sales were maintained by Allelock, an antiallergic agent, Patanol, an antiallergic ophthalmic solution and others, while sales of Coversyl, an ACE inhibitor for treatment of hypertension, that commenced in April, 2008, also performed well and contributed to growth in sales.
Table 30: Patanol franchise: sales forecast ($m), 2008-14 83